Abstract
Introduction F2-Isoprostanes (F2-IsoPs) and Isofurans (IsoF), specific markers of lipid peroxidation in vivo, have been reported to be elevated and have prognostic implications following subarachnoid hemorrhage (SAH). Platelet activation and vasoconstriction are attributed to these compounds. Elevated IsoF: F2-IsoPs ratios have been previously suggested as indicative of mitochondrial dysfunction. In this small study we examined their performance as specific biomarkers for delayed brain injury (DBI) development following SAH. We also explored if evidence of mitochondrial dysfunction could be found in a cohort of SAH patients.
Methods Eighteen patients with SAH and 7 controls with normal neuroimaging and CSF analysis results underwent CSF sampling and abstraction of clinical, demographic, and laboratory data. Samples (two) of CSF were collected on day 1 and once on days 5-8 post-bleed. F2-IsoP and IsoF assays were performed at Vanderbilt Eicosanoid Core Lab by gas chromatography/mass spectroscopy. Levels are expressed in median (IQR) for non-parametric data. Repeated sample measurement were compared using the Wilcoxon signed-rank test, whereas the Mann Whitney test was used for other non-parametric data.
Results Mean age was 61.2 + 15.7 (SAH cases) vs. 47.6 + 10 (controls) years, and 80% of SAH patients were female. Median Hunt-Hess score was 3 (2-4) and modified Fisher scale 3 (3-4). Thirty nine percent of patients developed DBI. F2-IsoP were significantly higher in SAH cases than in controls [47.5 (30.2-53.5) vs. 26.0 (21.2-34.5) pg/mL]. No significant differences were observed in patients with or without DBI [41 (33.5-52) vs. 44 (28.5-55.5) pg/mL]. IsoF were elevated in the second CSF sample in 9 patients, but undetectable in the remainder cases and all controls. Patients who developed DBI had significantly higher IsoF than cases who did not [(57 (34-72) vs. 0 (0-34) pg/mL]. Patients who met criteria for delayed injury had a significantly higher IsoF: F2IsoPs ratio on the late CSF sample [1.03 (1-1.38) vs. 0 (0-0.52)].
Conclusions Preliminary findings from this study suggest that IsoF may represent a specific biomarker predicting DBI following SAH and provide possible evidence of CNS mitochondrial dysfunction in SAH. Future studies to further explore the value of IsoF as biomarkers of secondary brain injury and the contribution of mitochondrial dysfunction and ferroptosis to clinical outcomes following SAH seem warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Drs. Gomes received grant funding in 2017 from The Aneurysm and AVM Foundation to conduct this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We conducted this clinical-translational work adhering to all local legal and ethical guidelines. All participants provided informed consent (or their respective next of kin/legal representatives), and IRB approval was obtained prior to the initiation of the study. All subjects were enrolled in the Cleveland Clinic, while CSF samples were analyzed at the University of Vanderbilt. A materials and data transfer agreement between both institutions was secured before any samples were transferred. Full approval was granted by the Cleveland Clinic IRB initially on 4/6/2017, and subsequent renewals submitted yearly. Ethical approval was given. The Institutional Review Board of The Cleveland Clinic Foundation: is duly constituted (fulfilling FDA requirements for diversity), allows only those IRB members who are independent of the investigator and the sponsor of the trial to vote on the trial, has written procedures for initial and continuing review of clinical trials, prepares written minutes of convened meetings, and retains records pertaining to the review and approval process; is all in compliance with requirements defined in 21 CFR Parts 50, 56, 312 and 812 and ICH (International Conference on Harmonization) guidelines relating to GCPs (Good Clinical Practice) that mirror FDA regulations. The Cleveland Clinic Foundation's Federalwide Assurance, FWA00005367, has been approved by the Office for Human Research Protections (OHRP) and expires 1/23/2025. You will find this approval listed on the OHRP website. Funding agencies use this website to verify that an institution holds an active OHRP-approved FWA. The Cleveland Clinic Foundation's IRB Organization Registration Information, IORG0000301, expires 2/28/2022 and can also be found on the OHRP website at the same address above.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.